With the arrival of the golden age of Chinese medicine innovation, the capacity-building of achievement transformation should be paid more attention to

In recent years, a series of pharmaceutical reform policies have been introduced and continued to advance, and the golden age of pharmaceutical innovation has arrived.
especially since 2015, the rapid development of new drug research and development in China, after several years of rapid development, China has become parallel with Europe and Japan, the world's second largest pharmaceutical innovation platform, pharmaceutical companies to improve the strength of research and development is obvious to all.
the golden age of Chinese pharmaceutical innovation (Photo: Pharmaceutical Network) Industry says new drugs from home and abroad are rapidly entering the Chinese market, with bio-start-ups dominated by new drugs emerging on a large scale.
market access, the adjustment of the national medical insurance catalogue and the procurement of volume have further stimulated the vitality of the domestic pharmaceutical market, and Chinese pharmaceutical innovation has entered a golden age.
with the advent of innovative drug market opportunities, in recent years, many enterprises in China have also stepped up the layout.
E.e. Synth Pharmaceuticals has nearly 50 innovative pharmaceutical products under development at various stages of development, including small molecule drugs, polymer drugs and CAR T cell therapy, of which more than 10 are in the clinical stage of research and innovation pharmaceutical products, have submitted new drug declarations or have been approved.
And Cynda Bio recently announced that the company and Lilly Pharmaceuticals jointly developed innovative drug Dabohua (Lytoxi single anti-biosimilar drug) has been approved by the State Drug Administration in China for the treatment of diffuse large B-cell lymphoma, filthy lymphoma and chronic lymphocytic leukemia, and for the company's fourth approved by the China Drug Administration listed drugs.
research on innovative drugs is of great significance for China to build an innovative country and reduce its dependence on new drugs abroad.
the development of innovative drugs, the industry stressed that the endo-dynamics of innovative research and development should be activated, with greater emphasis on basic research and capacity-building for the transformation of results.
can't be original without basic research and transformation, so China has to get basic research up, and that's a short board.
to promote the transformation of results, there are many enterprises to put efforts into it.
Sheng Zelin, chairman of TheRasse Pharmaceuticals, said it was "real to make the medicine" in the current capital rush.
is understood that in mid-January 2018, Ze-Yuan Pharmaceuticals announced the completion of 400 million yuan B round of financing, for the current round of funds raised, the company said that mainly for a number of chemical and biological new drugs for more than a dozen clinical trials.
It is understood that in the early days of its establishment, learn from the experience of large European and American companies have begun to develop large-molecule drugs and small-molecule drugs at the same time, from the company's long-term development strategy, in accordance with the positioning of a real pharmaceutical company and not just a research and development center to build Ze-Yu.
in order to be a real pharmaceutical company, five years ago Ze-Yuan began to prepare for the production of new chemical agents and biological new drug production industrialization platform.
research needs to improve conversion capability.
a mature pharmaceutical innovation environment, which requires a series of factors such as basic research, research and development system, policy support and market environment.
environment will better promote the development of innovative drugs, to Suzhou biopharmaceutical industry cluster, for example, it is the country's strategic emerging industrial cluster, ranking in the forefront of the country.
a short period of one year, Suzhou Industrial Park's biopharmaceutical industry, from more than 1000 enterprises in 19 years to more than 3000 this year, the development of rapid progress.
As relevant industry sources said, Suzhou Industrial Park has a very good environment for innovation and development, where they can make full use of their oncology clinical resources and Suzhou biopharmaceutical enterprises, medical institutions, research institutes to work closely together, so as to promote the steady and rapid development of the biopharmaceutical industry, help health China action, benefit tens of millions of cancer patients, reduce the economic burden on society.